A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

ProCure Proton Therapy Center Offers Non-Invasive Solution

ProCure Proton Therapy Center reports that Tom Corlett, a retired New Jersey resident, first learned of his brain tumor by accident, when sinus pain drove him to see his doctor. Several tests later, he was shocked to discover that it was not sinus pain but instead a golf-ball-sized meningioma brain tumor sitting right behind his nose.

As the tumor continued growing, Corlett braced himself for surgery, which he thought was the only viable option, although he was terrified of taking this invasive route.

But after more research, Corlett learned about a non-invasive option at ProCure Proton Therapy Center. Proton therapy is a highly advanced form of radiation treatment that, unlike standard radiation, safely and precisely destroys cancer cells while sparing surrounding healthy tissue.

In Corlett’s case, he chose ProCure because it effectively stopped the tumor from growing. “I had no residual effects from the procedure,” Corlett said. “Physically, I feel fine. I’m back to playing golf and chasing the grandkids around.”

Dr. Brian Chon, ProCure Proton Therapy Center Medical Director, said proton therapy’s precision makes it ideal for many types of cancers, including complex cases and recurrent tumors. Proton therapy can help preserve neurocognitive function by limiting doses to the normal, uninvolved brain when compared to X-ray based treatments.

“We are grateful to play a role in Tom’s journey,” Dr. Chon said. “Brain tumors can significantly impact quality of life, and they are sometimes near critical organs. This often makes proton therapy a good option.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy